Evidence map›Paper›PMID 36602577›Full record

ArticleWorld journal of urology2023

Investigating PSMA-PET/CT to resolve prostate MRI PIRADS4-5 and negative biopsy discordance.

Lih-Ming Wong, Samantha Koschel, Thomas Whish-Wilson, Matthew Farag, Damien Bolton, Homi Zargar, Niall Corcoran, Nathan Lawrentschuk, Alexandar Christov, Lauren Thomas and 4 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06494696 (Utilizing 68Ga-PSMA PET/MRI Imaging in Conjunction With mpMRI for Evaluating Prospective Prostate Cancer Risk), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06494696 recruitingnot on this mapstarted 2024, after this paper: background citation

Utilizing 68Ga-PSMA PET/MRI Imaging in Conjunction With mpMRI for Evaluating Prospective Prostate Cancer Risk

Typeobservational_patient_registrySponsorChang Gung Memorial HospitalRan2024 to 2027Enrolled71ConditionsProstate CancerArmsGa-68 PSMA PET/MRI
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lih-Ming WongDepartment of Urology, St Vincent's Health Melbourne, Melbourne, Australia. lihmingwong@gmail.com.ORCID http://orcid.org/0000-0003-0490-7876
Samantha KoschelDepartment of Urology, St Vincent's Health Melbourne, Melbourne, Australia.
Thomas Whish-WilsonDepartment of Urology, St Vincent's Health Melbourne, Melbourne, Australia.
Matthew FaragDepartment of Surgery, University of Melbourne, Melbourne, Australia.
Damien BoltonDepartment of Surgery, University of Melbourne, Melbourne, Australia.
Homi ZargarDepartment of Surgery, University of Melbourne, Melbourne, Australia.
Niall CorcoranDepartment of Surgery, University of Melbourne, Melbourne, Australia.
Nathan LawrentschukDepartment of Surgery, University of Melbourne, Melbourne, Australia.
Alexandar ChristovDepartment of Urology, St Vincent's Health Melbourne, Melbourne, Australia.
Lauren ThomasDepartment of Radiology, St Vincent's Health Melbourne, Melbourne, Australia.
Elisa PerryDepartment of Radiology, St Vincent's Health Melbourne, Melbourne, Australia.
Stefan HeinzeDepartment of Radiology, Melbourne Health, Melbourne, Australia.
Kim TaubmanDepartment of Radiology, St Vincent's Health Melbourne, Melbourne, Australia.
Tom SutherlandDepartment of Radiology, St Vincent's Health Melbourne, Melbourne, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo determine the utility of diagnostic 18F-DCPyL PSMA-PET/CT to aid management of men with highly suspicious multiparametric MRI prostate (PIRAD 4-5 lesions) and discrepant negative prostate biopsy.

methodsA multicentre prospective consecutive case series was conducted (2018-2021), recruiting men with prior mpMRI prostate PIRADS 4-5 lesions and negative prostate biopsy. All men had 18F-DCPyL PSMA-PET/CT with subsequent management based on the concordance between MRI and PET: (1) Concordant lesions were biopsied using in-bore MRI targeting; (2) PSMA-PET/CT avidity without MRI correlate were biopsied using cognitive/software targeting with ultrasound guidance and (3) Patients with negative PET/CT were returned to standard of care follow-up.

results29 patients were recruited with 48% (n = 14) having concordant MRI/PET abnormalities. MRI targeted biopsy found prostate cancer in six patients, with grade groups GG3 (n = 1), GG2 (n = 1), GG1 (n = 4) found. Of the 20 men who PSMA-PET/CT avidity and biopsy, analysis showed higher SUVmax (20.1 vs 6.8, p = 0.036) predicted prostate cancer. Of patients who had PSMA-PET avidity without MRI correlate, and those with no PSMA-PET avidity, only one patient was subsequently found to have prostate cancer (GG1). The study is limited by small size and short follow-up of 17 months (IQR 12.5-29.9).

conclusionsPSMA-PET/CT is useful in this group of men but requires further investigation. Avidity (higher SUVmax) that correlates to the mpMRI prostate lesion should be considered for targeted biopsy.

Indexed as

ProstateProstatic NeoplasmsBiopsyHumansMagnetic Resonance ImagingMalePositron Emission Tomography Computed TomographyProspective StudiesRadiopharmaceuticalsRadiopharmaceuticals18F-DCPyLmpMRI prostateProstate biopsyProstate cancerPSMA-PET/CT

Identifiers

PMID36602577

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.